Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAT1 | P18440 | 6/20 | 1.00 |
| ▸ | MYC | P01106 | 3/20 | 1.00 |
| ▸ | MAX | P61244 | 3/20 | 1.00 |
| ▸ | PIM1 | P11309 | 1/20 | 0.75 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.75 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.73 |
| ▸ | CISD1 | Q9NZ45 | 3/20 | 0.71 |
| ▸ | CA2 | P00918 | 1/20 | 0.71 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.71 |
| ▸ | MAOA | P21397 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | CRHBP | P24387 | 1/20 | 0.66 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.66 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.66 |
| ▸ | CLK1 | P49759 | 1/20 | 0.66 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.66 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.66 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.66 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20816059 | 1.00 | NAT1 (1.00) | NAT1MYCMAXPIM1PIM2 | |
| SCHEMBL1249069 | 1.00 | NAT1 (1.00) | NAT1MYCMAXPIM1PIM2 | |
| SCHEMBL261187 | 0.86 | PIM1 (1.00) | NAT1MYCMAXPIM1PIM2 | |
| SCHEMBL261188 | 0.86 | PIM1 (1.00) | NAT1MYCMAXPIM1PIM2 | |
| SCHEMBL2544039 | 0.86 | PIM1 (1.00) | NAT1MYCMAXPIM1PIM2 | |
| SCHEMBL1125091 | 0.85 | NAT1 (0.73) | NAT1MYCMAXCISD1CA2 | |
| SCHEMBL1125089 | 0.85 | NAT1 (0.73) | NAT1MYCMAXCISD1CA2 | |
| SCHEMBL12961168 | 0.85 | NAT1 (0.73) | NAT1MYCMAXCISD1CA2 | |
| SCHEMBL4054980 | 0.84 | MMP3 (0.78) | NAT1MYCMAXCISD1MAOA | |
| SCHEMBL4054985 | 0.84 | MMP3 (0.78) | NAT1MYCMAXCISD1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212568-A1 | MICRORNA-MEDIATED METHODS FOR REJUVENATING CNS GLIAL POPULATIONS | UNIVERSITY OF ROCHESTER | 2023-07-06 | — | — | US | disclosed |
| US-20230212568-A1 | MICRORNA-MEDIATED METHODS FOR REJUVENATING CNS GLIAL POPULATIONS | UNIVERSITY OF ROCHESTER | 2023-07-06 | — | — | US | disclosed |
| US-20230190961-A1 | COMPOSITIONS AND METHODS FOR TREATING MYELIN DEFICIENCY BY REJUVENATING GLIAL PROGENITOR CELLS | UNIVERSITY OF ROCHESTER | 2023-06-22 | — | — | US | disclosed |
| US-20230190961-A1 | COMPOSITIONS AND METHODS FOR TREATING MYELIN DEFICIENCY BY REJUVENATING GLIAL PROGENITOR CELLS | UNIVERSITY OF ROCHESTER | 2023-06-22 | — | — | US | disclosed |
| US-20230133695-A1 | METHODS AND COMPOSITIONS FOR REJUVENATING CNS GLIAL POPULATIONS BY SUPPRESION OF TRANSCRIPTION FACTORS | UNIVERSITY OF ROCHESTER | 2023-05-04 | — | — | US | disclosed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-7872027-B2 | Low molecular weight Myc-max inhibitors | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-01-18 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| EP-1610812-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN | NOVO NORDISK A/S (DK) | 2006-01-04 | — | — | EP | disclosed |
| EP-1605967-A1 | NOVEL NPH INSULIN PREPARATIONS | NOVO NORDISK A/S (DK) | 2005-12-21 | — | — | EP | disclosed |
| EP-1585541-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2005-10-19 | — | — | EP | disclosed |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | NOVO NORDISK A/S (DK) | 2005-03-24 | — | — | US | disclosed |
| WO-2004080481-A1 | NOVEL NPH INSULIN PREPARATIONS | NOVO NORDISK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004080480-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN | NOVO NORDISK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004056347-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
| EP-1429763-A2 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2004-06-23 | — | — | EP | disclosed |
| US-20030229120-A1 | Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer | NOVO NORDISK A/S (DK) | 2003-12-11 | — | — | US | disclosed |
| WO-2003027081-A2 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133695-A1 | METHODS AND COMPOSITIONS FOR REJUVENATING CNS GLIAL POPULATIONS BY SUPPRESION OF TRANSCRIPTION FACTORS | IKZF3, IKZF1, CXXC4 | NAT1 3536/4885MYC 19/4885MAX 558/4885 |
| US-20230190961-A1 | COMPOSITIONS AND METHODS FOR TREATING MYELIN DEFICIENCY BY REJUVENATING GLIAL PROGENITOR CELLS | TEAD2, MYT1, TEAD1 | NAT1 2135/4885MYC 32/4885MAX 2012/4885 |
| US-20230212568-A1 | MICRORNA-MEDIATED METHODS FOR REJUVENATING CNS GLIAL POPULATIONS | MYT1, STAT3, MYC | NAT1 3378/4885MYC 3/4885MAX 747/4885 |
| US-20030229120-A1 | Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer | IAPP, IRS1, GPR119 | NAT1 4334/4885MYC 3728/4885MAX 472/4885 |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | IAPP, IRS1, INSR | NAT1 4479/4885MYC 2234/4885MAX 75/4885 |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | NAT1 4542/4885MYC 2998/4885MAX 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.